CLINICAL_TRIALS
trial_result
· 2016-06-01
Clinical Trial Update: Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung [Phase 2]
Summary
Phase 2 clinical trial updating Dacomitinib (PF-00299804) as a single oral agent in selected patients with non-small cell lung adenocarcinoma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Carcinoma, Non-small Cell | Phase 2 | Status: COMPLETED | Results posted: 2016-06-01